当前位置： SCI文献检索 > BONE MARROW TRANSPLANTATION期刊下所有文献 > Graft failure in children receiving HLA-mismatched marrow transplants with busulfan-containing regimens.

Graft failure in children receiving HLA-mismatched marrow transplants with busulfan-containing regimens.

Abstract：

:Identifying risk factors that lead to graft failure may reduce morbidity and mortality after bone marrow transplantation (BMT) for hematologic malignancies. We evaluated engraftment of all patients with acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML) and myelodysplastic syndrome (MDS) receiving an unmanipulated marrow allogeneic BMT at the Detroit Medical Center from 1987 to 1992 using a busulfan, cyclophosphamide +/- cytarabine preparative regimen. Three of 118 patients had graft failure (2.5%; (95% confidence interval (CI) 0.7%, 6.4%). Graft failure was high in patients < or = 15 years with 3 of 12 patients with failure (25.0%) compared with 0 of 106 patients > 15 years (p = 0.002). Failure to engraft was not seen in HLA-identical (related or unrelated) donor transplants (0 of 103) whereas 3 of 15 HLA-mismatched donors failed (p = 0.003). Patient diagnosis, locus of HLA-mismatch, cytarabine in the preparative regimen, marrow cell dose and the relative reactive index (RRI) were not significant factors. Altered busulfan kinetics secondary to young age was probably not a major factor since 8 of 8 HLA-identical donor transplants engrafted in children. These findings demonstrate that patients receiving an unmanipulated marrow graft using busulfan-containing regimens were at a high risk for graft failure only if they were < or = 15 years of age and had an HLA-mismatched donor. More immunosuppressive preparative regimens, possibly including total body irradiation, should be considered to prevent potential graft failure in children.

journal_name

Bone Marrow Transplant

journal_title

Bone marrow transplantation

authors

Schultz KR,Ratanatharathorn V,Abella E,Eisenbrey AB,Karanes C,Lum LG,de Planque MM,Uberti JP,Ravindranath Y,Sensenbrenner LL

subject

Has Abstract

pub_date

1994-06-01 00:00:00

pages

817-22

issue

6

eissn

0268-3369

issn

1476-5365

journal_volume

13

pub_type

杂志文章

相关文献

BONE MARROW TRANSPLANTATION文献大全
  • A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation.

    abstract：:We initiated a randomized study of amifostine (the organic thiophosphate formerly known as WR-2721) given to patients during myeloablative conditioning therapy for allogeneic bone marrow transplantation. Amifostine was given at a dose of 1000 mg/day of conditioning and was well tolerated if attention was given to seru...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章,随机对照试验

    doi：10.1038/sj.bmt.1704521

    authors： Hwang WY,Koh LP,Ng HJ,Tan PH,Chuah CT,Fook SC,Chow H,Tan KW,Wong C,Tan CH,Goh YT

    更新日期：2004-07-01 00:00:00

  • ABO-incompatible bone marrow transplantation: a GITMO survey of current practice in Italy and comparison with the literature.

    abstract：:ABO incompatibility is not considered a contraindication for allogeneic haematopoietic stem cell transplantation (HSCT) despite its association with several immunohaematological complications. At present, there is no general agreement concerning the best methods to reduce these problems. To survey current practice rel...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/sj.bmt.1704579

    authors： Raimondi R,Soli M,Lamparelli T,Bacigalupo A,Arcese W,Belloni M,Rodeghiero F,Gruppo Italiano Trapianto di Midolla Osseo.

    更新日期：2004-08-01 00:00:00

  • 'Real-life' report on the management of chronic GvHD in the Gruppo Italiano Trapianto Midollo Osseo (GITMO).

    abstract：:Several guidelines have been published about management of chronic GvHD (cGvHD), but the clinical practice still remains demanding. The Gruppo Italiano Trapianto di Midollo Osseo (GITMO) has planned a prospective observational study on cGvHD, supported by a dedicated software, including the updated recommendations. In...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2017.223

    authors： Giaccone L,Mancini G,Mordini N,Gargiulo G,De Cecco V,Angelini S,Arpinati M,Baronciani D,Bozzoli V,Bramanti S,Calore E,Cavattoni IM,Cimminiello M,Colombo AA,Facchini L,Falcioni S,Faraci M,Fedele R,Guidi S,Iori AP,M

    更新日期：2018-01-01 00:00:00

  • Alefacept treatment for refractory chronic extensive GVHD.

    abstract：:Alefacept (Amevive) is an immunosuppressive dimeric fusion protein that is used for psoriasis control. We recently showed its effect in acute steroid-resistant/dependent GVHD. In this study, we describe the effect of alefacept treatment on chronic extensive GVHD (cGVHD). Twelve patients were included in this study; of...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2008.324

    authors： Shapira MY,Abdul-Hai A,Resnick IB,Bitan M,Tsirigotis P,Aker M,Gesundheit B,Slavin S,Or R

    更新日期：2009-02-01 00:00:00

  • Thyroid function after autologous bone marrow transplantation.

    abstract：:Thyroid function was prospectively analysed in 111 consecutive patients in relation to autologous bone marrow transplantation (ABMT). Median follow-up time was 12 (range 3-60) months. As part of the conditioning treatment 58 patients had received total body irradiation (TBI) as a single dose of 7.5 Gy (dose rate 0.15 ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Carlson K,Lönnerholm G,Smedmyr B,Oberg G,Simonsson B

    更新日期：1992-08-01 00:00:00

  • Collection of peripheral blood stem cells in multiple myeloma following single high-dose cyclophosphamide with and without recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF).

    abstract：:High-dose cyclophosphamide (HD-CY; 7 g/m2) was administered to patients suffering from high risk multiple myeloma (MM). The safety of this procedure, the recirculation and collection of peripheral blood stem cells (PBSC) and the effect of rhGM-CSF and HD-CY were studied. Group I patients (n = 21) were treated with HD-...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：

    authors： Boiron JM,Marit G,Fabéres C,Cony-Makhoul P,Foures C,Ferrer AM,Cristol G,Sarrat A,Girault D,Reiffers J

    更新日期：1993-07-01 00:00:00

  • Diagnosis of toxoplasmosis in bone marrow transplant recipients: comparison of PCR-based results and immunohistochemistry.

    abstract：:Toxoplasmosis in bone marrow transplant recipients is a rare but serious complication and if untreated, almost uniformly fatal. The diagnosis, however, remains difficult. We therefore compared serial determination of antibody titers specific for T. gondii before and after transplantation, serial PCR for T. gondii DNA ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702457

    authors： Held TK,Krüger D,Switala AR,Beyer J,Kingreen D,Busemann C,Janitschke K,Siegert W

    更新日期：2000-06-01 00:00:00

  • Allogeneic SCT in refractory or relapsed adult ALL is effective without prior reinduction chemotherapy.

    abstract：:We present 60 patients with refractory (n=8) or relapsed (n=52) adult ALL who received allogeneic hematopoietic SCT (HSCT) with (n=41) or without (n=19) prior reinduction chemotherapy. In our center, omission of reinduction is recommended if a suitable donor is promptly available, tumor burden is moderate and disease ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2008.258

    authors： Terwey TH,Massenkeil G,Tamm I,Hemmati PG,Neuburger S,Martus P,Dörken B,Hoelzer D,Arnold R

    更新日期：2008-12-01 00:00:00

  • Sensitivity of secondary acute myeloid leukemia relapsing after allogeneic bone marrow transplantation to immunotherapy with interferon-alpha 2b.

    abstract：:A patient with acute myeloid leukemia secondary to therapy of choriocarcinoma underwent T cell non-depleted allogeneic bone marrow transplantation from an unrelated donor in first untreated relapse. Persistent/relapsed leukemia 4 months after transplantation did not respond to cessation of cyclosporine. Due to logisti...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1700793

    authors： Singhal S,Powles R,Treleaven J,Mehta J

    更新日期：1997-06-01 00:00:00

  • Treatment of gonadal damage in recipients of allogeneic or autologous transplantation for haematological malignancies.

    abstract：:Management of iatrogenic gonadal reproductive failure and sexual morbidity assumes a priority, especially in young recipients of high-dose chemotherapy and stem cell transplantation (SCT). Hormone replacement treatment (HRT) is beneficial for correction of sexual symptoms and osteoporosis in both sexes, especially in ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/sj.bmt.1703721

    authors： Chatterjee R,Kottaridis PD

    更新日期：2002-11-01 00:00:00

  • Assessment of TREC, KREC and telomere length in long-term survivors after allogeneic HSCT: the role of GvHD and graft source and evidence for telomere homeostasis in young recipients.

    abstract：:Reconstitution of the adaptive immune system following allogeneic hematopoietic stem cell transplantation is crucial for beneficial outcome and is affected by several factors, such as GvHD and graft source. The impact of these factors on immune reconstitution has been thoroughly investigated during the early phase aft...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2017.216

    authors： Gaballa A,Norberg A,Stikvoort A,Mattsson J,Sundberg B,Uzunel M,Remberger M,Uhlin M

    更新日期：2018-01-01 00:00:00

  • In vivo cytokine responses to interleukin-2 immunotherapy after autologous stem cell transplantation in children with solid tumors.

    abstract：:The potent immunostimulatory cytokine interleukin-2 (IL-2) has been extensively investigated for its potential to induce anti-tumor immunity in a number of tumor models. Only recently the complex interplay of mutually suppressive or supportive cytokines of the IL-2-induced network of cytokines has been better characte...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1702431

    authors： Bönig H,Laws HJ,Wundes A,Verheyen J,Hannen M,Kim YM,Banning U,Nürnberger W,Körholz D

    更新日期：2000-07-01 00:00:00

  • Successful outcomes of second hematopoietic stem cell transplantation with total nodal irradiation and ATG conditioning for graft failure in adult patients with severe aplastic anemia.

    abstract：:Data regarding the optimal approach for second allogeneic hematopoietic stem cell transplantation (HSCT) after graft failure (GF) in acquired severe aplastic anemia (SAA) are still limited and heterogeneous. We examined 24 patients who underwent second HLA-matched sibling donor (MSD) peripheral blood HSCT for GF. The ...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/s41409-018-0154-0

    authors： Yahng SA,Park SS,Jeon YW,Yoon JH,Shin SH,Lee SE,Cho BS,Eom KS,Kim YJ,Lee S,Min CK,Kim HJ,Cho SG,Kim DW,Min WS,Lee JW

    更新日期：2018-10-01 00:00:00

  • New strategies in GVHD prophylaxis.

    abstract：:Despite immunosuppressive therapy using cyclosporine (CsA) and prednisolone and methotrexate (MTX), the incidence for aGVHD grade II to IV after transplantation from HLA matched unrelated donors (MUD) is 78%, the incidence for grade III and IV 36%. Since GVHD contributes to morbidity and mortality after MUD-BMT, a mor...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702346

    authors： Kiehl MG,Shipkova M,Basara N,Blau WI,Fauser AA

    更新日期：2000-05-01 00:00:00

  • Influence of marrow CFU-GM content on engraftment and survival after allogeneic bone marrow transplantation.

    abstract：:The influence of the CFU-GM content of donor marrow on the outcome of allogeneic marrow transplantation (BMT) has been debated. We now report 38 patients (25 acute leukemias, 10 chronic myeloid leukemias, two myeloma; 24 in first CR/CP and 14 in more advanced phases of their disease) undergoing unmanipulated HLA-ident...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Bacigalupo A,Piaggio G,Podesta M,Figari O,Benvenuto F,Sogno G,Tedone E,Raffo MR,Grassia L,Ferrero R

    更新日期：1995-02-01 00:00:00

  • Consensus opinion on immune-mediated cytopenias after hematopoietic cell transplant for inherited metabolic disorders.

    abstract：:Hematopoietic stem cell transplantation (HCT) has been increasingly used for patients with inherited metabolic disorders (IMD). Immune mediated cytopenias (IMCs) after HCT, manifesting as hemolytic anemia, thrombocytopenia, and/or neutropenia, are recognized as a significant complication in this patient population, ye...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/s41409-020-01179-5

    authors： Gupta AO,Jan Boelens J,Ebens CL,Kurtzberg J,Lund TC,Smith AR,Wagner JE,Wynn R,Blazar BR,Orchard PJ

    更新日期：2021-01-13 00:00:00

  • Lupus inhibitors following bone marrow transplant.

    abstract：:Lupus inhibitors have been reported in a number of pathologic states in which there is a disruption of normal immunoregulation. We report here the development of new lupus inhibitors following bone marrow transplantation. Retrospective analysis of 1292 patients undergoing transplantation at the University of Minnesota...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：

    authors： Greeno EW,Haake R,McGlave P,Weisdorf D,Verfaillie C

    更新日期：1995-02-01 00:00:00

  • High-dose chemotherapy with autologous PBSC transplantation for poor prognosis germ cell tumors: a retrospective monocenter analysis of 44 cases.

    abstract：:Germ cell cancer (GCC) is curable in metastatic stages. The International Germ Cell Cancer Collaborative Group (IGCCCG) reports a poor prognosis subgroup with a 5-year survival of 48%. High-dose chemotherapy with PBSC transplantation (HD-PBSCT) in these patients showed promising results in phase II, but failed to show...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,随机对照试验

    doi：10.1038/bmt.2012.14

    authors： Mohr M,Hartig I,Kessler T,Hamisch C,Kliesch S,Krug U,Spieker T,Semik M,Wiebe K,Pühse G,Hertle L,Liersch R,Müller-Tidow C,Mesters RM,Berdel WE

    更新日期：2012-10-01 00:00:00

  • Patients at high risk for CMV infection and disease show delayed CD8+ T-cell immune recovery after allogeneic stem cell transplantation.

    abstract：:Human cytomegalovirus (CMV) is a major cause of death after transplantation. The frequency of pp65-specific T cells was examined in 38 HLA-A2+ stem cell recipients during the first year after transplantation. Patients were divided into four groups based on donor/recipient serostatus: d+/r+ (n=17), d+/r- (n=7), d-/r+ (...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,多中心研究

    doi：10.1038/sj.bmt.1705585

    authors： Ganepola S,Gentilini C,Hilbers U,Lange T,Rieger K,Hofmann J,Maier M,Liebert UG,Niederwieser D,Engelmann E,Heilbronn R,Thiel E,Uharek L

    更新日期：2007-03-01 00:00:00

  • Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future.

    abstract：:beta-Thalassemia major and sickle cell disease (SCD) are among the most common hereditary disorders worldwide. The supportive treatment of beta-thalassemia major requires chronic, life-long RBC transfusions, which cause progressive iron overload and the potential for impaired endocrine, cardiac and hepatic function. T...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/sj.bmt.1705943

    authors： Bhatia M,Walters MC

    更新日期：2008-01-01 00:00:00

  • Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization.

    abstract：:Plerixafor is an inhibitor of CXCR-4 (CXC chemokine receptor-4)/SDF (stromal cell-derived factor)-1 binding used in combination with granulocyte colony-stimulating factor (G-CSF) for mobilization of autologous peripheral blood hematopoietic stem cells (HSCs). We developed a data-generated, cost-saving decision-making ...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2010.78

    authors： Costa LJ,Alexander ET,Hogan KR,Schaub C,Fouts TV,Stuart RK

    更新日期：2011-01-01 00:00:00

  • Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients.

    abstract：:The efficacy and safety of oral valganciclovir was compared to ganciclovir i.v. in pre-emptive treatment of cytomegalovirus (CMV) in T-cell-depleted allogeneic stem cell transplant (allo-SCT) recipients. A therapeutic guideline was developed to allow the safe application of valganciclovir in allo-SCT recipients requir...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1705311

    authors： van der Heiden PL,Kalpoe JS,Barge RM,Willemze R,Kroes AC,Schippers EF

    更新日期：2006-04-01 00:00:00

  • Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL.

    abstract：:We investigated the prognostic relevance of IKZF1 deletions in 118 adult Ph-positive ALL patients who had minimal residual disease (MRD) data under a uniform treatment of allo-SCT following first-line imatinib-based chemotherapy. IKZF1 deletions were identified in 93 patients (78.8%). IKZF1-deleted patients had a lowe...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2014.281

    authors： Kim M,Park J,Kim DW,Kim YJ,Jeon YW,Yoon JH,Shin SH,Yahng SA,Lee SE,Cho BS,Eom KS,Kim HJ,Min CK,Cho SG,Kim Y,Lee JW,Han K,Min WS,Lee S

    更新日期：2015-03-01 00:00:00

  • Growth and endocrine function in children with acute myeloid leukaemia after bone marrow transplantation using busulfan/cyclophosphamide.

    abstract：:Longitudinal studies of growth and endocrine function of children with AML transplanted with BUCY are limited. We report a cohort of 23 children with AML transplanted (15 autologous and eight allogeneic) following a single chemotherapy protocol and surviving at least 2 years after BMT. Busulfan was given as a single d...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1702384

    authors： Afify Z,Shaw PJ,Clavano-Harding A,Cowell CT

    更新日期：2000-05-01 00:00:00

  • Invasive fungal infections in lymphoma patients receiving immunotherapy following autologous bone marrow transplantation (ABMT).

    abstract：:Invasive fungal infections are quite rare (1-5%) following conventional ABMT for malignant lymphoma. Two high-risk lymphoma patients (one non-Hodgkin's lymphoma (NHL) and one Hodgkin's disease) underwent ABMT followed by immunotherapy as part of an experimental therapy given to 12 lymphoma patients aiming to prevent r...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/sj.bmt.1700847

    authors： Toren A,Or R,Ackerstein A,Nagler A

    更新日期：1997-07-01 00:00:00

  • The EBMT activity survey 2008: impact of team size, team density and new trends.

    abstract：:Six hundred and fifteen centers from 45 countries reported a total 30,293 HSCT to this 2008 EBMT survey with 26,810 first transplants (40% allogeneic, 60% autologous). This corresponds to an increase of 7% for the allogeneic and 3% for the autologous HSCT. Main indications were leukemias (32%; 89% allogeneic); lymphom...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/bmt.2010.69

    authors： Gratwohl A,Baldomero H,Schwendener A,Gratwohl M,Apperley J,Frauendorfer K,Niederwieser D

    更新日期：2011-02-01 00:00:00

  • Are new conditioning regimens for transplants in acute myelogenous leukemia better?

    abstract：:Pretransplant conditioning regimens designed to decrease leukemia relapse and increase leukemia-free survival in allotransplants in acute myelogenous leukemia (AML) were developed recently. We review studies of new regimens containing drugs like busulfan, cytarabine, melphalan or etoposide as well as novel radiation s...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：

    authors： Aurer I,Gale RP

    更新日期：1991-04-01 00:00:00

  • Controversies and challenges in HLA-haplotype-matched transplants for leukaemia.

    abstract：:Many typescripts in this issue describe increasing use of HLA-haplotype-matched transplants in persons with leukaemia and report outcomes. Consequently, my goal is not to repeat these data but to focus on controversies and challenges relevant to this topic including: (1) what is the best technique for performing these...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章

    doi：10.1038/s41409-019-0611-4

    authors： Gale RP

    更新日期：2019-08-01 00:00:00

  • Stem cell transplant for Waldenström macroglobulinemia: an underutilized technique.

    abstract：:Waldenström macroglobulinemia is a highly chemosensitive lymphoplasmacytic lymphoma with response rates of 90% to first-line chemotherapy. The fraction of patients undergoing stem cell transplant for this disorder appears to be lower than that of patients with multiple myeloma. The indolent nature and favorable geneti...

    journal_title：Bone marrow transplantation

    pub_type： 杂志文章,评审

    doi：10.1038/bmt.2011.175

    authors： Gertz MA,Reeder CB,Kyle RA,Ansell SM

    更新日期：2012-09-01 00:00:00

  • Stem cell transplantation in children with infantile osteopetrosis is associated with a high incidence of VOD, which could be prevented with defibrotide.

    abstract：:Malignant infantile osteopetrosis (MIOP) is a rare hereditary disorder of osteoclast function, which can be reversed by hematopoietic stem cell transplantation (SCT). We observed a high incidence of hepatic veno-occlusive disease (VOD) in transplanted patients and explored the prevention of this complication by using ...

    journal_title：Bone marrow transplantation

    pub_type： 临床试验,杂志文章

    doi：10.1038/sj.bmt.1705485

    authors： Corbacioglu S,Hönig M,Lahr G,Stöhr S,Berry G,Friedrich W,Schulz AS

    更新日期：2006-10-01 00:00:00